Promising eye disease drug trial halted early
NCT ID NCT04737330
First seen Apr 24, 2026 · Last updated May 19, 2026 · Updated 6 times
Summary
This study tested a drug called secukinumab for people with active, moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. The trial aimed to see if the drug could reduce eye swelling and bulging over 16 weeks. However, the study was stopped early, so the results are limited and only descriptive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Frankfurt, 60318, Germany
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Göttingen, 37075, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
Conditions
Explore the condition pages connected to this study.